Could a single daily pill replace complex HIV regimens?
NCT ID NCT00196612
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial compares a once-daily combination of three HIV drugs (emtricitabine, didanosine, and efavirenz) to the standard multi-pill regimen containing a protease inhibitor. The goal is to see if the simpler daily pill works just as well at keeping the virus undetectable, while causing fewer side effects and being easier for patients to take. The study includes adults with HIV who have had an undetectable viral load for at least six months on their current therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
emtricitabine, didanosine, efavirenz
What this could lead to
If successful, this could offer people with HIV a simpler, once-daily treatment option with fewer side effects and better quality of life.
What could go wrong
This is a phase 3 trial, so results are not yet confirmed. The once-daily combo may prove less effective or cause unexpected side effects in some people.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Service de Maladies Infectieuses, Hôpital Saint-Louis
Paris, 75475, France